Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery

Postoperative Vasoplegic Syndrome Clinical Trial

Official title: Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery

Status Recruiting

Clinical Trial Summary

Vasoplegic syndrome is a common complication after cardiac surgery. Low dose vasopressin can up-regulate blood pressure and improve clinical outcomes compared with norepinephrine (mainly acute kidney injury Anesthesiology 2017; 126:85-93). Pituitrin is used as a substitute for vasopressin in our center, which contains both vasopressin and oxytocin. Oxytocin may alleviate inflammatory process-associated kidney injury (Peptides 2006;27:2249-57). Therefore, the investigators hypothesize Pituitrin may be preferable to norepinephrine in the renal protection of patients with vasoplegic syndrome after cardiac surgery. Moreover, the serum levels of vasopressin, catecholamine, corticosteroid and corticotropin-releasing hormone will be measured.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Postoperative Vasoplegic Syndrome
• Syndrome
• Vasoplegia

• NCT number: NCT03106831
• Study type: Interventional
• Source: Beijing Anzhen Hospital
• Contact: Hong Wang, PhD., MD.
• Phone: 86 15010516438
• Email: 914286855@qq.com
• Status: Recruiting
• Phase: N/A
• Start date: October 10, 2017
• Completion date: April 30, 2019